Opthea Limited (OPT) - Long-Term Debt to Capital

Opthea Limited (OPT) develops innovative retinal therapies using a proprietary molecule combination method to bypass dominant market players. This price action chart on GURU.Markets illustrates the dynamics of debt obligations, which currently stand at 0.00. The issuer's financial stability is critically dependent on the success of a single key drug currently undergoing final stages of testing.

Assess the financial stability of Opthea Limited (OPT) by analyzing its liability structure. This metric compares the volume of loans with a maturity of over one year against the issuer's total equity. By analyzing the long-term debt-to-equity chart, an investor determines the extent to which development depends on borrowed funds. Low leverage here confirms the stability of the R&D core during the final stage of clinical trials. This ensures the retention of key ophthalmologists without the risk of emergency debt restructuring.